Program
SIRPa-4-1BBL Fusion Protein DSP107
Also written as “DSP107” and “DSP107 + Atezolizumab”.
Its studies are mostly in Colorectal Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Drug pageSIRPa-4-1BBL Fusion Protein DSP107: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kahr Medicalits history only | 21 open or running | phase 2since Jun 16, 2020 | Jun 16, 2020 | none ahead |
| Kahr Bio Australia Ptyits history only | 11 open or running | phase 2since Nov 3, 2025 | Nov 3, 2025 | none ahead |
Also a collaborator on its studies: Novotech (Australia) Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2020First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Kahr MedicalKahr Medical · NCT04440735 · 125 enrolled · United States
- Jun 6, 2021Phase 1 study in Leukemia, Myeloid, AcuteKahr Medical · NCT04937166 · 25 enrolled · United States
- Nov 3, 2025Kahr Bio Australia Pty’s first study: phase 2 study in Colorectal NeoplasmsNew to Kahr Bio Australia PtyKahr Bio Australia Pty · NCT07235293 · 90 planned · United States, Australia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07235293Colorectal Neoplasms · United States, Australia | 2 | Recruiting | Kahr Bio Australia Pty | Sep 30, 2026 | 90 |
| NCT04937166Leukemia, Myeloid, Acute · United States | 1 | Terminated | Kahr Medical | Apr 23, 2025 | 25 |
| NCT04440735Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Kahr Medical | Sep 2025 | 125 |
How it is read
Names in the registry
- “DSP107”, 2 entries
- “DSP107 + Atezolizumab”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Leukemia, Myeloid, Acute, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.